147 related articles for article (PubMed ID: 17077434)
1. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.
McCue RE; Waheed R; Urcuyo L; Orendain G; Joseph MD; Charles R; Hasan SM
Br J Psychiatry; 2006 Nov; 189():433-40. PubMed ID: 17077434
[TBL] [Abstract][Full Text] [Related]
2. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia.
Hatta K; Sato K; Hamakawa H; Takebayashi H; Kimura N; Ochi S; Sudo Y; Asukai N; Nakamura H; Usui C; Kawabata T; Hirata T; Sawa Y
Schizophr Res; 2009 Aug; 113(1):49-55. PubMed ID: 19553086
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
Kahn RS; Fleischhacker WW; Boter H; Davidson M; Vergouwe Y; Keet IP; Gheorghe MD; Rybakowski JK; Galderisi S; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Grobbee DE;
Lancet; 2008 Mar; 371(9618):1085-97. PubMed ID: 18374841
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Juncal-Ruiz M; Ramirez-Bonilla M; Gomez-Arnau J; Ortiz-Garcia de la Foz V; Suarez-Pinilla P; Martinez-Garcia O; Neergaard KD; Tabares-Seisdedos R; Crespo-Facorro B
Psychopharmacology (Berl); 2017 Sep; 234(17):2563-2570. PubMed ID: 28567698
[TBL] [Abstract][Full Text] [Related]
6. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
8. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
9. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
San L; Arranz B; Perez V; Safont G; Corripio I; Ramirez N; Dueñas R; Alvarez E
Psychiatry Res; 2012 Dec; 200(2-3):693-701. PubMed ID: 22954905
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).
Boter H; Peuskens J; Libiger J; Fleischhacker WW; Davidson M; Galderisi S; Kahn RS;
Schizophr Res; 2009 Dec; 115(2-3):97-103. PubMed ID: 19819114
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
[TBL] [Abstract][Full Text] [Related]
12. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
[TBL] [Abstract][Full Text] [Related]
13. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Villari V; Rocca P; Fonzo V; Montemagni C; Pandullo P; Bogetto F
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):405-13. PubMed ID: 17900775
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine versus haloperidol treatment in first-episode psychosis.
Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
[TBL] [Abstract][Full Text] [Related]
15. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
16. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
Volavka J; Czobor P; Derks EM; Bitter I; Libiger J; Kahn RS; Fleischhacker WW;
J Clin Psychiatry; 2011 Jul; 72(7):955-61. PubMed ID: 21824456
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
19. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.
Brook S; Walden J; Benattia I; Siu CO; Romano SJ
Psychopharmacology (Berl); 2005 Apr; 178(4):514-23. PubMed ID: 15650846
[TBL] [Abstract][Full Text] [Related]
20. Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study.
Skryabin VY; Vinnikova MA; Ezhkova EV; Titkov MS; Bulatova RA
J Addict Dis; 2021; 39(4):513-525. PubMed ID: 33832406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
